ExeVir, a Ghent, Belgium-based company developing single domain antibody therapies providing broad protection against viral infections, closed its Series A financing raising a total of US$50m.
The financing, announced in March 2021, was led by Fund+ with participation from VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices. In conjunction with the funding, Caroline Thielen, Investment Manager at SRIW will join the Board of ExeVir Bio alongside Torsten Mummenbrauer, CEO of ExeVir Bio, Philippe Monteyne, Partner at Fund+, Erica Whittaker, Head of UCB Ventures, Jérôme Van Biervliet, Managing Director at VIB, Stef Heylen representing SFPI-FPIM, Professor Michel Kazatchkine as independent director and Katja Rosenkranz, Partner at V-Bio Ventures (observer), Joel Henneghien at Vives IUF (observer) and Louis Declerck at Fund+ (observer).
The company is using the funds to commence the global phase 1b/2 clinical trial of lead compound XVR011 and develop a VHH72-Fc sub-cutaneous formulation for Covid-19 in parallel and accelerate development of its pipeline beyond Covid-19 in infectious diseases.
Led by Torsten Mummenbrauer, CEO, ExeVir Bio leverages the VHH technology platform to generate antiviral therapies providing broad protection against viral infections, including coronaviruses. It is a spin out from VIB, the world class Belgium-based life sciences research institute, based on the work of Professor Drs Xavier Saelens and Nico Callewaert from VIB in collaboration.
FinSMEs
24/05/2021